- Home
- KURA
KURA
Kura Oncology Inc.
as 09-06-2024 4:00pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.5B | IPO Year: | N/A |
| Target Price: | $30.60 | AVG Volume (30 days): | 434.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.41 - $24.17 | Next Earning Date: | 10-31-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kura Oncology Inc. News
KURA Breaking Stock News: Dive into KURA Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now
Associated Press Finance
a month ago
Kura Oncology: Q2 Earnings Snapshot
GlobeNewswire
a month ago
Kura Oncology Reports Second Quarter 2024 Financial Results
MT Newswires
a month ago
Kura Oncology Says FDA Clears Ziftomenib Clinical Study in Advanced GIST
GlobeNewswire
a month ago
Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
GlobeNewswire
a month ago
Kura Oncology to Report Second Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Compare KURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.